Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
Healthcare
$1.30 +3.57%
+$0.06 today
- Market cap
- $182.35M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
52W Low $1.33High $2.26
Volume 0.50M
Average 1.03M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$51.97M
FY 2025 · Annual
Net Income
-$48.26M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.1M | 123.44K | 260.5K | 0 | 0 |
| Cost of Revenue | 11.36M | 6.72K | 13.62M | 26.27K | 0 |
| Gross Profit | (8.26M) | 116.72K | (13.36M) | (26.27K) | 0 |
| Gross Margin | -266.4% | 94.6% | -5127.8% | — | — |
| Research & Development | 11.36M | 12.03M | 13.62M | 17.21M | 29.79M |
| Selling, General & Admin | 0 | 6.21M | 6.73M | 11.38M | 23.56M |
| Operating Expenses | 6.51M | 18.25M | 6.73M | 28.56M | 51.97M |
| Depreciation & Amortization | 14.77M | 6.72K | 177.4K | 26.27K | 60.5K |
| EBITDA | 0 | (18.05M) | (18.85M) | (27.49M) | (53.29M) |
| EBITDA Margin | 0.0% | -14620.4% | -7236.7% | — | — |
| Operating Income | (14.77M) | (18.13M) | (20.09M) | (28.59M) | (51.97M) |
| Operating Margin | -476.2% | -14686.2% | -7712.0% | — | — |
| Interest Income | 19.92K | 74.45K | 1.06M | 1.07M | 3.72M |
| Interest Expense | 19.92K | 74.45K | 0 | 0 | 0 |
| Other Income / Expenses | (19.92K) | 74.45K | 1.06M | 1.07M | 3.72M |
| Income Before Tax | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Pre-Tax Margin | -476.9% | -14625.9% | -7304.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Net Margin | -476.9% | -14625.9% | -7304.8% | — | — |
| EPS (Basic) | (4.88) | (4.26) | (3.57) | (1.16) | (0.49) |
| EPS (Diluted) | (4.88) | (4.26) | (3.57) | (1.16) | (0.49) |
| 3.03M | 4.2M | 5.33M | 69.36M | 98.31M | |
| 3.03M | 4.2M | 5.33M | 69.36M | 98.31M |
IKT Earnings Waterfall · TTM
NASDAQ:IKT · Revenue to Net Income
Key Ratios
EPS$-0.54
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$51.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.54, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 21, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 21, 2026 | |
| 8-K | Current report | Oct 20, 2026 |
How much revenue does IKT generate?
Inhibikase Therapeutics, Inc. (IKT) reported $0.00 of revenue in fiscal 2025.
Is IKT profitable?
Inhibikase Therapeutics, Inc. (IKT) reported -$48.26M of net income.
Continue the stock analysis
Jump to another research area for this company.